Company research
ADMA BIOLOGICS, INC.
CIK 1368514Updated Sep 27, 2026
SecurityADMA · NASDAQ · equity
Name history
R&R ACQUISITION VI, INC · through Feb 21, 2012
ADMA price & chart
Loading TradingView…
NASDAQ:ADMA on TradingView ↗About the company
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human - slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., w…
In the news
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) ↗
ADMA DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA ↗
ADMA DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 624,242,000Source | 488,678,000Source | 329,182,000Source | 348,461,881Source |
| Property, Plant and Equipment, NetUSD | 65,057,000Source | 54,707,000Source | 53,835,000Source | 58,261,481Source |
| GoodwillUSD | 3,530,000Source | 3,530,000Source | 3,530,000Source | 3,529,509Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 632,000Source | 460,000Source | 499,000Source | 1,013,415Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 87,630,000Source | 103,147,000Source | 51,352,000Source | 86,521,542Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 158,429,000Source | 49,999,000Source | 27,421,000Source | 15,505,048Source |
| Inventory, NetUSD | 206,465,000Source | 170,235,000Source | 172,906,000Source | 163,280,047Source |
| Assets, CurrentUSD | 466,512,000Source | 331,410,000Source | 257,013,000Source | 270,401,783Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,458,000Source | 8,029,000Source | 5,334,000Source | 5,095,146Source |
| Operating Lease, Right-of-Use AssetUSD | 6,650,000Source | 8,634,000Source | 9,635,000Source | 10,485,447Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 146,922,000Source | 139,660,000Source | 193,976,000Source | 196,487,666Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 24,000Source | 24,000Source | 23,000Source | 22,182Source |
| Additional Paid in CapitalUSD | 671,039,000Source | 657,577,000Source | 641,439,000Source | 629,968,704Source |
| Retained Earnings (Accumulated Deficit)USD | -161,653,000Source | -308,583,000Source | -506,256,000Source | -478,016,671Source |
| Stockholders' Equity Attributable to ParentUSD | 477,320,000Source | 349,018,000Source | 135,206,000Source | 151,974,215Source |
| Liabilities and EquityUSD | 624,242,000Source | 488,678,000Source | 329,182,000Source | 348,461,881Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 69,541,000Source | 55,542,000Source | 49,806,000Source | 39,266,942Source |
| Operating Lease, Liability, CurrentUSD | 1,096,000Source | 1,218,000Source | 1,045,000Source | 905,369Source |
| Accounts Payable, CurrentUSD | 22,519,000Source | 20,219,000Source | 15,660,000Source | 13,229,390Source |
| Operating Lease, Liability, NoncurrentUSD | 6,646,000Source | 8,561,000Source | 9,779,000Source | 10,704,176Source |
| Other Liabilities, NoncurrentUSD | 0Source | 360,000Source | 419,000Source | 350,454Source |
| Additional Financial Items | ||||
| Deferred Revenue, NoncurrentUSD | 1,405,000Source | 1,547,000Source | 1,690,000Source | 1,833,031Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 2,813,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 69,330,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 8,000,000Source | 7,700,000Source | 7,600,000Source | 6,400,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 20,026,000Source | 13,616,000Source | 6,187,000Source | 5,214,531Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 108,430,000Source | 22,578,000Source | 11,916,000Source | -13,071,809Source |
| Increase (Decrease) in InventoriesUSD | 36,230,000Source | -2,671,000Source | 9,626,000Source | 38,555,957Source |
| Increase (Decrease) in Accounts PayableUSD | 2,330,000Source | 4,150,000Source | 3,839,000Source | 799,981Source |
| Deferred Income Tax Expense (Benefit)USD | 11,020,000Source | -84,280,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 50,396,000Source | 118,672,000Source | 8,800,000Source | -59,508,257Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -21,891,000Source | -8,575,000Source | -4,981,000Source | -13,911,171Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 22,575,000Source | 8,226,000Source | 4,771,000Source | 13,911,171Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 31,940,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -44,022,000Source | -58,302,000Source | -38,989,000Source | 108,851,852Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -15,517,000Source | 51,795,000Source | -35,170,000Source | 35,432,424Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 87,630,000Source | 103,147,000Source | 51,352,000Source | 86,521,542Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 9,078,000Source | 10,668,000Source | 18,051,000Source | 13,879,958Source |
| Income Taxes Paid, NetUSD | 19,683,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 144,000Source | 388,000Source | 724,000Source | 715,353Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -9,000Source | -106,000Source | -182,000Source | -426,536Source |
| Gain (Loss) on Extinguishment of DebtUSD | -3,336,000Source | -1,243,000Source | -26,174,000Source | -6,669,941Source |
| GoodwillUSD | 3,530,000Source | 3,530,000Source | 3,530,000Source | 3,529,509Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 35,726,000Source | -71,959,000Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | 7,110,000Source | 13,930,000Source | — | — |
| Investment Income, InterestUSD | 1,871,000Source | 2,097,000Source | 1,617,000Source | 44,833Source |
| Net Income (Loss) Attributable to ParentUSD | 146,930,000Source | 197,673,000Source | -28,239,000Source | -65,903,950Source |
| Nonoperating Income (Expense)USD | -8,787,000Source | -13,269,000Source | -49,871,000Source | -26,538,870Source |
| Operating ExpensesUSD | 101,322,000Source | 80,570,000Source | 67,310,000Source | 74,630,237Source |
| Operating Lease, ExpenseUSD | 2,400,000Source | 2,400,000Source | 2,400,000Source | 2,100,000Source |
| Other Nonoperating Income (Expense)USD | -212,000Source | -193,000Source | -287,000Source | -634,389Source |
| Payments of Financing CostsUSD | 0Source | 0Source | 2,351,000Source | 2,782,928Source |
| Proceeds from Issuance of Common StockUSD | — | 0Source | 0Source | 64,645,289Source |
| Proceeds from Stock Options ExercisedUSD | 2,984,000Source | 7,494,000Source | 1,104,000Source | 175,015Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 510,173,000Source | 426,454,000Source | 258,215,000Source | 154,079,692Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 91,580,000Source | 74,124,000Source | 59,020,000Source | 52,458,024Source |
| Operating Income (Loss)USD | 191,443,000Source | 138,983,000Source | 21,632,000Source | -39,365,080Source |
| Other Nonoperating Income (Expense)USD | -212,000Source | -193,000Source | -287,000Source | -634,389Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 182,656,000Source | 125,714,000Source | — | — |
| Income Tax Expense (Benefit)USD | 35,726,000Source | -71,959,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | 146,930,000Source | 197,673,000Source | -28,239,000Source | -65,903,950Source |
| Earnings Per Share, BasicUSD per share | 0.62Source | 0.85Source | -0.13Source | -0.33Source |
| Earnings Per Share, DilutedUSD per share | 0.6Source | 0.81Source | -0.13Source | -0.33Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 238,299,024Source | 233,084,236Source | 223,977,315Source | 197,874,895Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 244,904,640Source | 243,342,466Source | 223,977,315Source | 197,874,895Source |
| Interest Expense (non-operating)USD | 7,110,000Source | 13,930,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 144,000Source | 388,000Source | 724,000Source | 715,353Source |
| Current Income Tax Expense (Benefit)USD | 24,706,000Source | 12,321,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 8,096,000Source | 8,045,000Source | 8,332,000Source | 7,113,369Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 292,765,000Source | 219,553,000Source | 88,942,000Source | 35,265,157Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 182,656,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 25,027,000Source | 19,279,373Source |
| Investment Income, InterestUSD | 1,871,000Source | 2,097,000Source | 1,617,000Source | 44,833Source |
| Marketing and Advertising ExpenseUSD | 3,100,000Source | 2,700,000Source | 3,300,000Source | 2,200,000Source |
| Nonoperating Income (Expense)USD | -8,787,000Source | -13,269,000Source | -49,871,000Source | -26,538,870Source |
| Operating ExpensesUSD | 101,322,000Source | 80,570,000Source | 67,310,000Source | 74,630,237Source |
| Operating Lease, ExpenseUSD | 2,400,000Source | 2,400,000Source | 2,400,000Source | 2,100,000Source |
| Other Cost and Expense, OperatingUSD | 4,836,000Source | 4,245,000Source | 4,266,000Source | 17,843,096Source |
| Research and Development ExpenseUSD | 4,762,000Source | 1,813,000Source | 3,300,000Source | 3,613,764Source |
Filing attachments
ef20079311_ex99-1.htm · 8-K · 2026-08-05
EX-99.1 2 ef20079311_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update 2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvement in Demand and Revenue 2Q 2026 GAAP Net Income of $37.8 Million, Increasing 11% Year-over-Year 2Q 2026 Adjusted Net Income(1) of $39.0 Millio…
Read attachment ↗ef20072554_ex99-1.htm · 8-K · 2026-05-06
EX-99.1 2 ef20072554_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update 1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income(1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA(2) of $59.7 Million, Representing 24% Year-Over-Year Growth 1Q 2026 Cash from Operations of $58 Millio…
Read attachment ↗ef20072196_ex99-1.htm · 8-K · 2026-05-04
EX-99.1 2 ef20072196_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIVTM to Include Pediatric Immune Compromised Patients Two Years of Age and Older RAMSEY, N.J. and BOCA RATON, Fla., May 4, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced the U.…
Read attachment ↗ef20069109_ex99-1.htm · 8-K · 2026-03-27
EX-99.1 2 ef20069109_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines Highlights that Demand for - and Utilization of - ASCENIV Has Grown Steadily Over Pa…
Read attachment ↗ef20066774_ex99-1.htm · 8-K · 2026-03-02
EX-99.1 2 ef20066774_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative RAMSEY, N.J. and BOCA RATON, Fla., March 2, 2026 - ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return…
Read attachment ↗ef20066393_ex99-1.htm · 8-K · 2026-02-25
EX-99.1 4 ef20066393_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income FY 2025 Adjusted EBITDA Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Ca…
Read attachment ↗